Date: 2016-03-08
Type of information: R&D agreement
Compound: novel therapeutic peptides
Company: Ipsen (France) Peptimimesis (France)
Therapeutic area: Cancer - Oncology
Type agreement: R&D licensing commercialisation
Action mechanism: peptide
Disease:
Details: * On March 8, 2016, Ipsen and PeptiMimesis announced the signature of a research partnership and a licensing option for the development and marketing of novel therapeutic peptides in oncology. Ipsen will combine its expertise in peptide design and development with PeptiMimesis knowledge in the identification of transmembrane peptides
and intracellular signaling. The target receptor is involved in different phases of cancer development, including angiogenesis, immune tolerance and proliferation. Under the terms of the agreement, Ipsen and PeptiMimesis will work closely together to move the project forward towards clinical development.
Financial terms: PeptiMimesis will receive financial support from Ipsen for the research phases, as well as milestone payments associated to the program. In the event the option is exercised, Ipsen could make further potential payments to PeptiMimesis at development, regulatory and commercial milestones, as well as royalty payments on worldwide annual net sales.
Latest news:
